RSS feedProstate cancer PCA3 tests
The PCA3 Test is a new genetic test that determines whether products of genes associated with prostate cancer are present in the urine. Up to 100 times more PCA3 is present in prostate cancer cells than non-cancerous cells.
What does the PCA3 score tell you?
A numerical score is obtained and the value of this gives an idea on how likely prostate biopsies are to show prostate cancer. The data is new, but guidelines are as follows:
| PCA3 score |
Probability of prostate cancer on biopsy |
|---|---|
| <5 | 14% |
| 5–19 | 26% |
| 20–34 | 37% |
| 35–49 | 47% |
| 50–100 | 55% |
| >100 | 78% |
The PCA3 test does not confirm or rule out prostate cancer and the chance of prostate cancer is variable.
However, the PCA3 score is significantly better than PSA alone, and when used in conjunction with the PSA value, digital rectal examination findings, age, prostate size and percentage free PSA, it is possible to make a better estimate about the risk of biopsy-detectable prostate cancer.
“We would not suggest that any single test provides all the answers, but in combination, we now have a much more effective range of tools for assessing men at risk of prostate cancer and deciding whether a biopsy is needed.”
Marc Laniado, Consultant Urologist,
Harley Street Urology
How does the PCA3 score compare with PSA?
The results are more accurate than PSA alone, but are not sufficient to rely on in isolation. The PCA3 score is not affected by the size of the prostate, unlike PSA. The PCA3 test is also less affected by urinary infections, which can make PSA completely unreliable.
